Molecular Biology Program
The Paul Tempst Lab
The principal interest of our group is to improve technology, strategies, and micro-methods for polypeptide isolation, mass spectrometric protein identification, and mapping of modified amino acids. The program draws from conventional biochemistry as well as from the fields of chemistry and engineering. These novel tools have found widespread use in the health and life sciences as a resource for the larger research community, and for our own studies on gene expression, proteomics of the human transcriptional machinery, protein modification profiling, and serum peptide diagnostics.
Nazarian A, Lawlor K, Yi SS, Philip J, Ghosh M, Yaneva M, Villanueva J, Saghatelian A, Assel M, Vickers AJ, Eastham JA, Scher HI, Carver BS, Lilja H, Tempst P. Inhibition of circulating DPP4 activity in patients with metastatic prostate cancer. Mol Cell Proteomics 2014; 13:3082-3096. PMCID: PMC4223493
Taylor JM, Yaneva M, Velasco K, Philip J, Erdjument-Bromage H, Ostrovnaya I, Lilja HG, Bochner BH, Tempst P. Aminopeptidase activities as prospective urinary biomarkers for bladder cancer. Proteomics Clinical Applic 2014; 8:317-326. PMCID: PMC4059539
Tempst P. Mass-encoded, synthetic biomarkers and multiplexed urinary monitoring. Clin Chem 2013; 59:1694-1695.
Root A, Allen P, Tempst P*, Yu K*. Protein Biomarkers for Early Detection of Pancreatic Ductal Adenocarcinoma: Progress and Challenges. Cancers (Basel) 2018; 10: 67; doi:10.3390/cancers10030067.
Huang FK, Zhang G, Lawlor K, Nazarian A, Philip J, Tempst P, Dephoure N, Neubert TA. Deep Coverage of Global Protein Expression and Phosphorylation in Breast Tumor Cell Lines Using TMT 10-plex Isobaric Labeling. J Proteome Res 2017; 16:1121-1132. PMCID: PMC5336479
Paul Tempst, PhD
- Molecular biologist Paul Tempst focuses on the development of proteomic technologies and approaches for studying the eukaryotic transcriptional machineries and for cancer biomarker discovery.
- PhD, Universiteit Gent
- Executive Committee Member, National Cancer Institute’s Clinical Proteomic Technologies Assessment for Cancer initiative (2006-2011)
- Council Member, US Human Proteome Organization (2004-2012)
- Discovery and molecular identification/characterization of the following: NFkappaB; IkappaB; NF-E2; PI3K; mTOR; Raptor; p27kip; SNAREs; histone-deacetylases, -methylases, and -demethylases; and the Mediator, Elongator, Polycomb, RSC, Swi/Snf, Compass, and Exosome complexes
- Use of protease activities as biomarkers for cancer
Get in Touch
Doctors and faculty members often work with pharmaceutical, device, biotechnology, and life sciences companies, and other organizations outside of MSK, to find safe and effective cancer treatments, to improve patient care, and to educate the health care community.
MSK requires doctors and faculty members to report (“disclose”) the relationships and financial interests they have with external entities. As a commitment to transparency with our community, we make that information available to the public.
Paul Tempst discloses the following relationships and financial interests:
No disclosures meeting criteria for time period
The information published here is for a specific annual disclosure period. There may be differences between information on this and other public sites as a result of different reporting periods and/or the various ways relationships and financial interests are categorized by organizations that publish such data.
This page and data include information for a specific MSK annual disclosure period (January 1, 2021 through disclosure submission in spring 2022). This data reflects interests that may or may not still exist. This data is updated annually.